Navigation Links
'Stent 4 Life': A campaign is launched to increase the use of primary PCI in acute coronary patients
Date:3/20/2009

A campaign which will reduce mortality in patients with acute coronary syndromes has been launched today by a coalition which includes the ESC Working Group on Acute Cardiac Care and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). "Stent 4 Life" is a project designed to encourage the wider use of reperfusion therapy with percutaneous coronary interventions (PCI, with balloon angioplasty and stent) in Europe. According to a new report introducing the campaign, it is the "unpredictable bursts" in coronary artery disease which lead to sudden ischaemic death, heart attack and unstable angina, and with them a sharp increase in mortality rate to more than 10%.(1)

Indeed, new European guidelines on the management of heart attack emphasise not only speed of action but also the importance of reperfusion to restore blood flow to the heart and improve survival rates.(2)

The Stent 4 Life campaign particularly addresses treatment of a common type of classical heart attack known as STEMI (ST-segment elevation acute myocardial infarction), a reference to its appearance on an ECG. Around one-third of all acute coronary events are diagnosed as STEMI, and the greater application of PCI (to rates above 600 per million population) "would enable us to address the needs of most patients suffering from STEMI across Europe".

The report adds: "The mission of the Stent 4 Life coalition is to promote the lifesaving indications of PCI, implying that priority will be given to targeting invasive resources to those patient groups who will benefit the most. Rather than attempting to enforce top down directives, the program will rely entirely on national Interventional Working Groups and Societies. Synergy, rather than competition, with existing initiatives will be the goal."

"There is first class evidence that primary PCI for acute STEMI is now the gold standard of care," says ESC spokesperson Professor Jean Fajadet, from the Clinique Pasteur in Toulouse, France. "But what we have seen is that its use in STEMI patients varies throughout Europe. In those countries with a high rate of PCI such as Denmark, Poland, Czech Republic and the Netherlands the number of untreated patients is low. Conversely, in countries with a low use of primary PCI the number of untreated patients is high."

The Stent 4 Life campaign aims to identify those countries where the use of primary PCI can be encouraged, and thereby the quality of care improved. The basis for the campaign is a questionnaire study with local cardiac societies in Europe and an assessment of individual requirements for a national programme. The recently announced National Infarct Angioplasty Project in the UK is one such action plan.

"We are convinced that this action will be of benefit to all," says the report. "Engaging in Stent 4 Life is simply the right thing to do, and at this early stage, we trust and rely on the active involvement of the entire interventional community."

Current registry data suggest that around 20-30 per cent of all STEMI patients in Europe still receive no reperfusion therapy. However, the report suggests that adherence to the guidelines and a greater use of primary PCI could dramatically improve STEMI patient survival.


'/>"/>

Contact: ESC Press Office
press@escardio.org
0033-492-948-627
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System
2. Bioabsorbable stents show promise
3. Drugs Before Stents for Stable Heart Disease, Study Says
4. Researchers Report Combined Molecules in Red Wine by Far Exceed the Biological Activity of Plain Resveratrol, Consistent With the Composition of Longevinex(R)
5. Drug-Eluting Stents Show Promise for Leg Arteries
6. Promising Three-year Data: Saving Limbs With Drug-Eluting Stents
7. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
8. SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents
9. Is Bypass Truly Better than Stenting?
10. Noninvasive screening test may detect narrowing in intracranial stents
11. Volunteer work in grade schools produces persistent health benefit for older black women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... speaker, trainer and author Ray Clarke poses a question as a challenge for ... In his book, "Being in the Being" (published by Partridge Singapore), Clarke explores ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance Group in Orange ... assist the people of their local community. The agency pledges to select a ... Their hope is to bring awareness to important local causes with fundraising and ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... multi-specialty practice Village Family Practice , will be presenting at the 2016 ... in Las Vegas, Nev. , During his session, “ Coding for Care: ...
(Date:2/11/2016)... ... 11, 2016 , ... The annual list showcases the 20 Most Promising SharePoint ... dedication and commitment to the SharePoint ecosystem. A panel of experts and members ... is to recognize and promote technology entrepreneurship. , The survey was made at ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... de fevereiro de 2016  A Proliant Biologicals ... de soroalbumina bovina (BSA -- Bovine Serum ... na Ilha Norte da Nova Zelândia, em Feilding. ... na fábrica da Proliant nos EUA, localizada em ... e instalação dos equipamentos foram feitos de forma ...
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions and the ... achieved through NPS and Dyax acquisitions and the announced combination ... through NPS and Dyax acquisitions and the announced combination with ... robust pipeline in Shire , s history   ... pipeline in Shire , s history   ...
(Date:2/11/2016)... , February 11, 2016 Breast Cancer ... the Asia-Pacific (APAC) breast cancer market ... $3.4 billion by 2021, at a Compound Annual Growth Rate ... Asia-Pacific Markets to 2021 - states that the ... considerable expansion from $1.9 billion in 2014 to $3.4 billion ...
Breaking Medicine Technology: